Recent Updates
Recently added Catalysts
IRWD Positive Sentiment

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

Tuesday, December 12, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ironwood Pharmaceuticals has announced the successful completion of its squeeze-out merger with VectivBio. This merger is expected to enhance Ironwood's capabilities and product offerings in the biopharmaceutical market. The strategic integration aims to leverage VectivBio's assets and expertise to further strengthen Ironwood's position.
Price reaction · baseline $10.21 (2023-12-11 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ironwood successfully completed the merger with VectivBio.
  • The merger may enhance Ironwood's product pipeline.
  • This strategic move could strengthen their market position.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)

Full Press Release Details

• Company Company Overview Leadership Open Payments & Transparency
• Science & Medicine Therapeutic Focus Pipeline Product
• Patients Overview
• Responsibility Overview Diversity, Equity & Inclusion Sustainability Safety & Compliance Patients & Research Community Giving
• Careers Working at Ironwood Internships, Co-ops and Fellowships Open Positions
• Investors & Media Contact Us
• Company Overview
• Leadership
• Open Payments & Transparency
• Therapeutic Focus
• Pipeline
• Product
• Overview
• Overview
• Diversity, Equity & Inclusion
• Sustainability
• Safety & Compliance
• Patients & Research
• Community Giving
• Working at Ironwood
• Internships, Co-ops and Fellowships
• Open Positions
• Investors & Media
• Contact Us

Frequently Asked Questions

What is the recent merger involving Ironwood?

Ironwood has completed a squeeze-out merger with VectivBio.

What are the expected benefits of the merger?

The merger is expected to enhance Ironwood's product pipeline and market position.

ShareAdd on Google
Tags: IRWD Viatris Investor Conferences Healthcare Ironwood VectivBio merger biopharmaceuticals
Last updated: Dec 12, 2023

Biotech snapshot

Cash runway
$79M liquidity · $0M/mo burn
Low dilution risk
Lead asset
IW-3718Phase 3
Gastroesophageal Reflux Disease (GERD) →

Catalyst track record

+57%
best trade around IRWD's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for IRWD.

See every catalyst's timing & PoA →